Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REGN5668 + ubamatamab + sarilumab
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
REGN5668 + ubamatamab + sarilumab is an experimental combination of three monoclonal antibodies with immunotherapeutic mechanisms, investigated primarily for ovarian cancer and related gynecologic malignancies. REGN5668 is a bispecific antibody that targets MUC16 (CA125) on tumor cells and CD28 on T cells to co-stimulate T-cell cytotoxicity. Ubamatamab (also known as REGN4018) is a bispecific antibody targeting MUC16 and CD3, facilitating T-cell mediated killing of MUC16-positive cancer cells. Sarilumab is a monoclonal antibody targeting the interleukin-6 receptor (IL-6R) and is approved for rheumatoid arthritis. While clinical trials have evaluated REGN5668 with other agents (cemiplimab or REGN4018), there are currently no major studies combining all three agents (REGN5668, ubamatamab, and sarilumab) together; this combination may be hypothetical or under preclinical consideration. REGN5668 and ubamatamab are both developed by Regeneron, as is sarilumab, and all are designed to stimulate and modulate the immune response against cancer, especially in MUC16-positive recalcitrant ovarian cancers[1][2][3][6].
- Other names
- REGN5668 + ubamatamab + sarilumab
02
Targets
CD28 (Cluster of Differentiation 28)CD3 (T-cell surface glycoprotein CD3)IL-6R (Interleukin-6 receptor subunit alpha)MUC16 (Mucin-16)
Beyond the preview
Go deeper on REGN5668 + ubamatamab + sarilumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGN5668 + ubamatamab + sarilumab.